Cnat stock price target
28 Jan 2020 Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) and Histogen Inc., “We believe the target product profile of our product candidates combined risks related to the market price of Conatus' common stock relative to the Split History. Stock splits are used by Conatus Pharmaceuticals Inc. to keep share prices within reasonable numbers to encourage investment. If the share price 13 Feb 2019 However, I think retail investors may disagree with their price target. My viewpoint is that the stock price would be over $12 since 3 top-line data I got the impression a lot of you hated CNAT stock that is full of third tiered Conatus Pharmaceuticals (CNAT) Stock Soars on Positive Liver Drug Trial Results Mobileye (MBLY) Stock Sinks After Morgan Stanley Cuts Price Target. Stock analysis for Conatus Pharmaceuticals Inc (CNAT:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and CNAT Stock Price, Forecast & News (Conatus Pharmaceuticals)
Conatus Pharmaceuticals Inc (CNAT): Analyst Looks Forward ...
Conatus Pharmaceuticals Inc. (CNAT) Stock Price, Quote ... Conatus Pharmaceuticals Inc. (CNAT) and Histogen Inc., a privately-held regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, today announced the companies have entered into a definitive agreement under which Histogen will merge with a wholly-owned subsidiary of Conatus in an all-stock Stifel slashes price target on Conatus Pharmaceuticals Inc ... Jan 30, 2020 · The new note on the price target was released on February 08, 2018, representing the official price target for Conatus Pharmaceuticals Inc. stock. Previously, the target price had yet another drop from $18 to $17, while H.C. Wainwright kept a Buy rating on CNAT stock. CONATUS PHARMACEUTICALS INC. : CNAT Stock Price ... Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. Conatus Pharmaceuticals Inc., CNAT Quick Chart - (NAS ...
CNAT - Conatus Pharmaceuticals Inc. Basic Chart, Quote and financial news from the leading provider and award-winning BigCharts.com. Conatus Pharmaceuticals stock price target cut to $12 from $20 at SunTrust RH MarketWatch. 07:40 AM ET. Conatus Pharmaceuticals stock price target cut to $4 from $10 at Stifel Nicolaus MarketWatch. 07:39 AM ET.
1 equities research analysts have issued 1-year target prices for Conatus Pharmaceuticals' stock. Their forecasts range from $1.50 to $1.50. On average, they CNAT | Complete Conatus Pharmaceuticals Inc. stock news by MarketWatch. Conatus Pharmaceuticals stock price target cut to $12 from $20 at SunTrust RH. See Conatus Pharmaceuticals price target based on analysts offering 12 month price targets for Conatus Pharmaceuticals in the last 3 months. Follow CNAT to Analyst price targets provided by TipRanks. Quick Links. Advanced Charting · After Hours Quote · Analyst Research
Analyst price targets provided by TipRanks. Quick Links. Advanced Charting · After Hours Quote · Analyst Research
Conatus Pharmaceuticals Inc's stock rating is based on fundamental analysis. Don't miss CNAT stock next rating changes Analysts Have Mixed Ratings On SunOpta Inc. (NASDAQ:STKL ... ROTH Capital also rated CNAT as Initiated on February 08, 2018, with its price target of $20 suggesting that CNAT could surge by 76.25% from its current share price. Even though the stock has been trading at $0.41/share, analysts expect it to down by -5.98% to reach $1.60/share. Conatus Pharmaceuticals Inc. (CNAT) Stock Price, Quote ... Conatus Pharmaceuticals Inc. (CNAT) and Histogen Inc., a privately-held regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, today announced the companies have entered into a definitive agreement under which Histogen will merge with a wholly-owned subsidiary of Conatus in an all-stock
Analyst price targets provided by TipRanks. Quick Links. Advanced Charting · After Hours Quote · Analyst Research
CNAT Stock Quote - Conatus Pharmaceuticals Inc. Common ... Mar 27, 2020 · Stock quote for Conatus Pharmaceuticals Inc. Common Stock Common Stock (CNAT) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq. CNAT - Conatus Pharmaceuticals Inc Stock quote - CNNMoney.com Find real-time CNAT - Conatus Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. CNAT - Conatus Pharmaceuticals Inc Stock quote - CNNMoney.com Markets CNAT | Conatus Pharmaceuticals Inc. Analyst Estimates ... CNAT updated stock price target summary. Dow Jones, a News Corp company. News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services.
Conatus Pharmaceuticals (CNAT) PT Lowered to $14 at H.C. Wainwright Conatus Pharmaceuticals (CNAT) PT Lowered to $10 at Oppenheimer Stifel Downgrades Conatus Pharmaceuticals (CNAT) to Hold CNAT | Conatus Pharmaceuticals Inc. Stock Price & News - WSJ Oct 30, 2019 · Conatus Pharmaceuticals Inc. historical stock charts and prices, analyst ratings, financials, and today’s real-time CNAT stock price. DOW JONES, A NEWS CORP COMPANY. News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services. Ride Out The Next Market Storm With FuelCell Energy Inc ... Mar 09, 2020 · ROTH Capital also rated CNAT as Initiated on February 08, 2018, with its price target of $20 suggesting that CNAT could surge by 75.63% from its current share price. Even though the stock has been trading at $0.42/share, analysts expect it to down by -7.78% to reach $1.60/share. Conatus Pharmaceuticals (CNAT) Stock Price History | wallmine